Investor Relations
Invest in the Future of Precision Medicine with Capitainer
Capitainer offers a unique platform for self-sampling of fingertip blood and plasma based on a patented microfluidic technology. Our platform for self-sampling is a unique enabler of two megatrends in healthcare: distance healthcare solutions, and personalized medicine where regular monitoring is essential.
The Capitainer Solution: Simplifying Clinical Testing
Today there are no other clinical micro-sampling devices that automatically extract plasma from whole blood. By providing universally applicable precision sampling technologies we want to improve healthcare outcomes for all and facilitate equal access to healthcare diagnostics for everyone, everywhere.
Each year, 890 million tests of clinical biomarkers are conducted in Europe and the US. These tests are essential tools in both medical decision-making and diagnosis, and approximately 70% of all medical decisions are based on laboratory results. Traditional blood sampling methods necessitate patients visiting healthcare facilities, involve laborious processes with venous blood sampling and require cold-chain transportation to laboratories. This creates high costs and inconveniences for patients, particularly those with low mobility or in remote locations.
Capitainer offers a high-precision, self-sampling platform suitable for blood, plasma, and urine samples. The technology has a nearly 100% success rate in clinical blood collection and allows for precise sampling equivalent to traditional methods. The samples can be sent via regular mail in standard envelopes, eliminating the need for specialized transportation.
A Snapshot of the Target Market
The total blood testing market is anticipated to reach USD 140.3 billion by 2028, whereas the total market for urinalysis is expected to reach USD 4.9 billion by 2026. Long-term demand on the clinical market is driven by, among other things, the increasing prevalence of chronic diseases and higher adoption of precision medicine, where regular monitoring is required, as well as healthcare at a distance. Other markets include doping tests and drug controls by the police.
Capitainer targets a position as the leading supplier of high-precision self-sampling solutions and a challenger of venous blood sampling for applications where self-sampling is beneficial.
Blood testing market by 2028
140.3
Billion USD
Urinalysis Market by 2026
4.9
Billion USD
Precision Products for Microsampling
The technology platform is based on dried spot matrix, where small volumes of blood or urine are collected and dried for analysis at the laboratory. Capitainer has, as of today, three products on the market that allow self-sampling with the market’s leading precision and reproducibility.
Our technology is protected by a broad patent portfolio in major geographic markets and the strategy is to continually seek patents for new innovations. The company currently has six patent families.
Collects 10 microliters of separated fingertip blood and is suitable for analysis of, for example biomarkers etc. diagnosed in plasma.
Collects 10 microliters of fingertip blood and is suitable for analysis of biomarkers and drugs in the fields of e.g. PKU-monitoring, antiepileptics, diabetes, hormones, steroids and kidney.
Collects 50 microliters of fingertip blood and is suitable for e.g. viral diseases and analyses of hormones and doping substances.
Based on Capitainer®B and designed specifically for the analysis of the alcohol marker PEth. It overcomes the well-known issue of post-sample creation of PEth in traditional venous blood sampling.
Leading in a Competitive Field: Accuracy with a Sustainable Revenue Model
While there are other solutions for microsampling of blood, there is no other solution that offers the same sampling accuracy and ease of use as Capitainer.
To drive long-term demand and high sales volumes, Capitainer’s focus during the upcoming years is to build market awareness and reference cases together with strategically important partners, customers and collaborators. Capitainer’s products are disposable devices, meaning that Capitainer receives recurring revenue from its customers. The pricing is in line with competing sampling devices and has been confirmed with potential customers (care facilities and laboratories).
Rooted in Excellence: Meet the Capitainer Team
Capitainer AB is a Swedish privately held medtech company founded in 2016 by clinicians and researchers from Karolinska Institutet and KTH Royal Institute of Technology.
The Capitainer team has a solid mix of competence and experience of life sciences and research in bioanalysis, sampling technologies and nanotechnologies, product development, sales and business development. Capitainer’s team consists of employees, board members and an advisory board.
Interested in learning more about Capitainer, exploring investment opportunities or considering a partnership with us?
Our friendly customer support team is here to answer any enquiries.